Documente Academic
Documente Profesional
Documente Cultură
Magnesium
salts Carbonatea6 Chloride3E* g11r"1"3s,aot Fumaratea3 Gluconate3E* Glycinateas
E lem ent al 2 3 2( 1 s . 0 ) 6 4 (5 .2 6) -(25) 530 (44.16) 27 (2.2,tabl ets) 100 ( 8. 33)
Mg++/
54 (4,4,ti qui d)
dos e,m g
(mEq)
S ofubilit y Nearly High Very good Good Moderate G ood
in water insoluble
is known concerning the extent of absorption of mag- The baseline excretion rate of magnesium was signifi-
nesium after a cathartic dose of magnesium sulfatl. cantly conelated with that of creatinine (R = .975j and
The bioavailability of magnesium after a large oral inorganic sulfate (R = .921). AIt the subjects experi-
dose of magnesium sulfate in normal volunte&s *us enced mild or moderate diarrhea. Therefore, the au-
examined in the current investigation. Baseline 2* thors concluded that magnesium is absorbed to a lim-
hour urinary excretion rates of magnesium and creat- ited and variable extent in healthy adults after a ca-
inine were determined over 3 corrsecutive days in six thartic dose of magnesium sulfate.2s
healthy men. The oral administration of 13.d g (56.s Magnesium sulfate is also the agent most commonly
mmole) magnesium sulfate U.S.p., in four equal used for treatrnent of edampsia and prophylaxis in
hourly increments, resulted in the urinary excretion patients with severe pre-edampsia. It is usually glven
(corrected for baseline excretion rate) of 4.0 t 2.9o/o by either the intramuscular or inbavenous route. The
(mean t SD) of the dose of magnesium during the first intramuscular regimen is most commonly a +g intra-
24 hours and 5.0 x, 7.0o/oof the dose during i Z}-hou, venous loading dose, immediately followed by 10 g
interval. Magnesium sulfate administration had no ef- intramuscularly and then by 5 g every 4 hours in al-
fect on the 24-hour urinary excretion rate of creatinine. ternating buttocks. The intravenous regimen is given
e001.) g,5)
AnrericanJonrnalof Therapeutics
BI OAVAILABILITY/PHARMACOKINETICS OF MAG
NESI UM
353
KMg D L L Hydrox-
L-lactateaE,aes Oxide37,4o citrate4l*r aspaft ate4taspartate"t idea+t Salicylats36ll Sulfatea2# Aminoate60
84 (71 241 119-8l| -(2 4 .5 ) 5 2x10.3 600 56.5mmotes 500 ( 41. 6)
mmol
AmericnnJournalof Therapeutics
Q00l) BG)